Evidence map›Paper›PMID 39335516›Full record

ReviewBiomedicines2024

A Comparative Review of Tocosomes, Liposomes, and Nanoliposomes as Potent and Novel Nanonutraceutical Delivery Systems for Health and Biomedical Applications.

Omar Atrooz, Elham Kerdari, M R Mozafari, Nasim Reihani, Ali Asadi, Sarabanou Torkaman, Mehran Alavi, Elham Taghavi

Abstract readReview
In one paragraph

Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Omar AtroozDepartment of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, Al-Ahliyya Amman University, Amman 19328, Jordan.ORCID 0000-0003-0610-5201
Elham KerdariAustralasian Nanoscience and Nanotechnology Initiative (ANNI), Monash University LPO, Clayton 3800, Australia.
M R MozafariAustralasian Nanoscience and Nanotechnology Initiative (ANNI), Monash University LPO, Clayton 3800, Australia.ORCID 0000-0002-4118-1544
Nasim ReihaniAustralasian Nanoscience and Nanotechnology Initiative (ANNI), Monash University LPO, Clayton 3800, Australia.ORCID 0009-0003-8004-3907
Ali AsadiAustralasian Nanoscience and Nanotechnology Initiative (ANNI), Monash University LPO, Clayton 3800, Australia.
Sarabanou TorkamanAustralasian Nanoscience and Nanotechnology Initiative (ANNI), Monash University LPO, Clayton 3800, Australia.
Mehran AlaviAustralasian Nanoscience and Nanotechnology Initiative (ANNI), Monash University LPO, Clayton 3800, Australia.ORCID 0000-0002-5691-8326
Elham TaghaviFaculty of Fisheries and Food Science, Universiti Malaysia Terengganu, 21030 Kuala Nerus, Terengganu, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Contemporary nutraceutical and biomedical sectors are witnessing fast progress in efficient product development due to the advancements in nanoscience and encapsulation technology. Nutraceuticals are generally defined as food substances, or a section thereof, that provide us with health benefits such as disease prevention and therapy. Nutraceutical and biomedical compounds as well as food supplements are a natural approach for attaining therapeutic outcomes with negligible or ideally no adverse effects. Nonetheless, these materials are susceptible to deterioration due to exposure to heat, oxygen, moisture, light, and unfavorable pH values. Tocosomes, or bilayered lyotropic vesicles, are an ideal encapsulation protocol for the food and nutraceutical industries. Biocompatibility, high entrapment capacity, storage stability, improved bioavailability, site specific delivery, and sustained-release characteristics are among the advantages of this nanocarrier. Similar to liposomal carriers and nanoliposomes, tocosomes are able to encapsulate hydrophilic and hydrophobic compounds separately or simultaneously, offering synergistic bioactive delivery. This manuscript describes different aspects of tocosome in parallel to liposome and nanoliposome technologies pertaining to nutraceutical and nanonutraceutical applications. Different properties of these nanocarriers, such as their physicochemical characteristics, preparation approaches, targeting mechanisms, and their applications in the biomedical and nutraceutical industries, are also covered.

Indexed as

biomedicinedrug deliveryencapsulationliposomenanoliposomenanonutraceuticaltocosome

Identifiers

PMID39335516
PMCPMC11429494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.